JPRN-UMIN000000466已完成未知
Japan Cooperative SPECT Study of Mild Impairment of Cognitive Function - J-COSMIC
J-COSMIC Executive Committee0 个研究点目标入组 500 人开始时间: 2006年8月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Significant neurological or psychiatric disease Neurological abnormality Psychiatric symptom
研究者
相似试验
招募中
不适用
Japan-systemic sclerosis observational study and registrySystemic sclerosisJPRN-UMIN000047794PO Japan PH Registry800
已完成
不适用
Observation study for Japanese patients with head and neck cancer by combination therapy with cetuximabsquamous-cell carcinoma of head and neckJPRN-UMIN000011911Japanese Oncology Radiation Study Group300
已完成
2 期
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33
进行中（未招募）
3 期
An extension study for seven patients in Japan with neuromyelitis optica spectrum disorder who completed the open-label period of study CD-IA-MEDI-551-1155 of InebilizumabJPRN-jRCT2051210017Sato Toshiyuki7
未知
1 期
A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of AZD2171 Alone and in Combination With AZD2171 and Pac/CarbCarcinoma, Non-Small-Cell LungJPRN-jRCT2080220478AstraZeneca